Current tools available for the diagnosis of drug-resistant tuberculosis

Therapeutic Advances in Infectious Disease

Volumn 3, Issue 6, 2016, Pages 145-151

  Gilpin, Christopher ^a   Korobitsyn, A ^a   Weyer, K ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

diagnosis; drug resistance; laboratory; tuberculosis

Indexed keywords

ETHIONAMIDE; ISONIAZID; PROTIONAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATION; CULTURE MEDIUM; DIAGNOSTIC ACCURACY; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; FLUORESCENCE; GENE; GENE MUTATION; GENOTYPE; GYRA GENE; GYRB GENE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; OXYGEN TENSION; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RAPID TEST; REVIEW;

EID: 85140806985     PISSN: 20499361     EISSN: 2049937X     Source Type: Journal    
DOI: 10.1177/2049936116673553     Document Type: Review

References (23)

1. Ängeby A., Juréen P., Kahlmeter G., Hoffner S., Schön T., (2012) Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 90: 693–698.
2. Böttger E., (2011) The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 17: 1128–1134.
3. Canetti G., Froman S., Grosset J., Hauduroy P., Langerová M., Mahler H.. (1963) Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 29: 565–578.
4. Frick M., Lessem E., McKenna L., (2016) Diagnostics, Treatment, Prevention and Vaccines in Development (Tuberculosis Edition). London; New York: HIV i-Base/Treatment Action Group.
5. Global Laboratory Initiative (GLI). (2015) Guide for Providing Technical Support to TB Laboratories in Low- and Middle-Income Countries. Geneva: GLI (a working group of the Stop TB Partnership).
6. Kambli P., Ajbani K., Sadani M., Nikam C., Shetty A., Udwadia Z.. (2015) Defining multidrug-resistant tuberculosis: correlating GenoType MTBDRplus assay results with minimum inhibitory concentrations. Diagn Microbiol Infect Dis 82: 49–53.
7. Machado D., Perdigão J., Ramos J., Couto I., Portugal I., Ritter C.. (2013) High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. J Antimicrob Chemother 68: 1728–1732.
8. Morlock G., Metchock B., Sikes D., Crawford J., Cooksey R., (2003) ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 47: 3799–3805.
9. Rieder H., Van Deun A., (2016) Letter to editor: rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. In Press.
10. Van Deun A., Aung K., Bola V., Lebeke R., Hossain M., de Rijk W.. (2013) Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 51: 2633–2640.
11. Vilcheze C., Wang F., Arai M., Hazbón M., Colangeli R., Kremer L.. (2006) Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 12: 1027–1029.
12. World Health Organization (WHO). (2007) Use of Liquid TB Culture and Drug Susceptibility Testing (DST) in Low and Medium Income Settings: Summary Report of the Expert Group Meeting on the Use of Liquid Culture Media. Geneva: WHO. Available at: http://www.who.int/tb/laboratory/use_of_liquid_tb_culture_summary_report.pdf?ua=1
13. World Health Organization (WHO). (2013) Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children. Geneva: WHO, 2013.
14. World Health Organization (WHO). (2014a) High-Priority Target Product Profiles for New Tuberculosis Diagnostics: Report of a Consensus Meeting. Geneva: WHO.
15. World Health Organization (WHO). (2014b) Tuberculosis Diagnostics Technology and Market Landscape, 3rd edn. Geneva: WHO.
16. World Health Organization (WHO). (2015a) Implementing the End TB Strategy: The Essentials. Geneva: WHO.
17. World Health Organization (WHO). (2015b) Implementing Tuberculosis Diagnostics: Policy Framework. Geneva: WHO.
18. World Health Organization (WHO). (2016a) Global Tuberculosis Report. Geneva: WHO.
19. World Health Organization (WHO). (2016b) Strategic and Technical Advisory Group for Tuberculosis (STAG-TB): Report of the 16th Meeting. Geneva: WHO.
20. World Health Organization (WHO). (2016c) The Use of Molecular Line Probe Assays for the Detection of Resistance to Isoniazid and Rifampicin: Policy Guidance. Geneva: WHO.
21. World Health Organization (WHO). (2016d) The Use of Molecular Line Probe Assays for the Detection of Resistance to Second-Line Anti-Tuberculosis Drugs: Policy Guidance. Geneva: WHO.
22. World Health Organization (WHO). (2016e) WHO Treatment Guidelines for Drug-Resistant Tuberculosis. Geneva: WHO.
23. Zignol M., Dean A., Alikhanova N., Andres S., Cabibbe A., Cirillo D.. (2016) Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. Available at: http://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(16)30190-6.pdf